London, UK-based biotechnology firm Onyvax says that it has begun a new Phase IIb clinical trial of its immunostimulatory agent, Onyvax-P, which is being developed to treat prostate cancer.
The study, which is being conducted at the US National Cancer Institute in Bathesda, Maryland, is designed to assess the drug in 44 patients with rising prostate-specific antigen levels after receiving localized therapy for primary prostate cancer. Participants will receive three months of androgen deprivation therapy before being randomized to receive 15 administrations of either Onyvax-P, or placebo, over a 12-month period. The program will examine the vaccine's effect on PSA-defined disease progression, PSA doubling time, testosterone recovery and immunological response.
Onyvax said that the NCI study will run in parallel to its ongoing Phase IIb trial of Onyvax-P in non-metastatic hormone-refractory prostate cancer that is being carried out at centers in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze